Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.

Cheung KWK, Yoshida K, Cheeti S, Chen B, Morley R, Chan IT, Sahasranaman S, Liu L.

Drug Metab Dispos. 2019 Sep;47(9):966-973. doi: 10.1124/dmd.119.087924. Epub 2019 Jul 2.

PMID:
31266752
2.

Correction to: Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.

Cheeti S, Hou HH, Nelson E, Walker H, Chen B, Morley R, Gates M, Musib L, Girish S, Sahasranaman S, Liu L.

Pharm Res. 2018 Oct 26;35(12):244. doi: 10.1007/s11095-018-2529-8.

PMID:
30367284
3.

Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example.

Chen Y, Zhu R, Ma F, Mao J, Chen EC, Choo EF, Sahasranaman S, Liu L.

Biopharm Drug Dispos. 2018 Nov;39(9):420-430. doi: 10.1002/bdd.2159. Epub 2018 Nov 20.

PMID:
30335192
4.

Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.

Cheeti S, Hou HH, Nelson E, Walker H, Chen B, Morley R, Gates M, Musib L, Girish S, Sahasranaman S, Liu L.

Pharm Res. 2018 Oct 15;35(12):233. doi: 10.1007/s11095-018-2516-0. Erratum in: Pharm Res. 2018 Oct 26;35(12):244.

5.

Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects.

Liu L, Cheeti S, Yoshida K, Choo E, Chen E, Chen B, Gates M, Singel S, Morley R, Ware J, Sahasranaman S.

J Clin Pharmacol. 2018 Nov;58(11):1427-1435. doi: 10.1002/jcph.1261. Epub 2018 May 22.

PMID:
29786857
6.

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.

Infante JR, Hollebecque A, Postel-Vinay S, Bauer TM, Blackwood EM, Evangelista M, Mahrus S, Peale FV, Lu X, Sahasranaman S, Zhu R, Chen Y, Ding X, Murray ER, Schutzman JL, Lauchle JO, Soria JC, LoRusso PM.

Clin Cancer Res. 2017 May 15;23(10):2423-2432. doi: 10.1158/1078-0432.CCR-16-1782. Epub 2016 Nov 4.

7.

A supported liquid extraction LC-MS/MS method for determination of concentrations of GDC-0425, a small molecule Checkpoint kinase 1 inhibitor, in human plasma.

Ding X, Chen Y, Sahasranaman S, Shi Y, McKnight J, Dean B.

Biomed Chromatogr. 2016 Dec;30(12):1984-1991. doi: 10.1002/bmc.3775. Epub 2016 Jul 5.

PMID:
27245274
8.

Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach.

Gadkar K, Lu J, Sahasranaman S, Davis J, Mazer NA, Ramanujan S.

J Lipid Res. 2016 Jan;57(1):46-55. doi: 10.1194/jlr.M057943. Epub 2015 Nov 1.

9.

Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy.

Lee L, Gupta M, Sahasranaman S.

J Clin Pharmacol. 2016 Feb;56(2):157-69. doi: 10.1002/jcph.591. Epub 2015 Sep 29. Review.

PMID:
26183909
10.

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.

Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil IS, Yalamanchili S, Chai A, Sahasranaman S, Punnoose E, Hurst D, Pylypenko H.

Leuk Lymphoma. 2015;56(10):2826-33. doi: 10.3109/10428194.2015.1030638. Epub 2015 May 12.

11.

Strategies to address drug interaction potential for antibody-drug conjugates in clinical development.

Lu D, Sahasranaman S, Zhang Y, Girish S.

Bioanalysis. 2013 May;5(9):1115-30. doi: 10.4155/bio.13.76. Review.

PMID:
23641700
12.

The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.

Grégoire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S, Gomez-Mancilla B, Di Paolo T.

Parkinsonism Relat Disord. 2011 May;17(4):270-6. doi: 10.1016/j.parkreldis.2011.01.008. Epub 2011 Feb 15.

PMID:
21315648
13.

Clinical pharmacology and pharmacogenetics of thiopurines.

Sahasranaman S, Howard D, Roy S.

Eur J Clin Pharmacol. 2008 Aug;64(8):753-67. doi: 10.1007/s00228-008-0478-6. Epub 2008 May 28. Review.

PMID:
18506437
14.

Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma.

Mortimer KJ, Harrison TW, Tang Y, Wu K, Lewis S, Sahasranaman S, Hochhaus G, Tattersfield AE.

Br J Clin Pharmacol. 2006 Oct;62(4):412-9.

15.

Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids.

Issar M, Sahasranaman S, Buchwald P, Hochhaus G.

Eur Respir J. 2006 Mar;27(3):511-6.

16.

Metabolism of mometasone furoate and biological activity of the metabolites.

Sahasranaman S, Issar M, Hochhaus G.

Drug Metab Dispos. 2006 Feb;34(2):225-33. Epub 2005 Oct 26.

PMID:
16251254
17.
18.

A sensitive liquid chromatography-tandem mass spectrometry method for the quantification of mometasone furoate in human plasma.

Sahasranaman S, Tang Y, Biniasz D, Hochhaus G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 May 5;819(1):175-9.

PMID:
15797536
19.

Characterization of degradation products of mometasone furoate.

Sahasranaman S, Issar M, Tóth G, Horváth G, Hochhaus G.

Pharmazie. 2004 May;59(5):367-73.

PMID:
15212303

Supplemental Content

Loading ...
Support Center